25-Hydroxyvitamin D3 loading test in primary hyperparathyroidism, hypoparathyroidism and pseudohypoparathyroidism

Area of Science:

• Endocrinology
• Metabolic Bone Disease

Background:

• Plasma 1,25-dihydroxyvitamin D (1,25-(OH)2D) is a key indicator of parathyroid function.
• Vitamin D levels may influence 1,25-(OH)2D levels.

Purpose of the Study:

• To investigate parathyroid function by assessing plasma 1,25-(OH)2D response to 25-hydroxyvitamin D3 (25OHD3) administration.
• To compare this response in primary hyperparathyroidism (1° HPT), hypoparathyroidism (HP), pseudohypoparathyroidism (PHP), and normal subjects.

Main Methods:

• Oral administration of 100 micrograms of 25OHD3 to 9 patients with 1° HPT, 7 with HP, 2 with PHP, and 6 normal subjects.
• Measurement of plasma 25-hydroxyvitamin D (25OHD) and 1,25-(OH)2D levels at baseline and after 25OHD3 administration.
• Statistical analysis to determine the significance of changes in 1,25-(OH)2D levels.

Main Results:

• Plasma 25OHD levels peaked 6-12 hours post-25OHD3 administration in all groups.
• A statistically significant increase in plasma 1,25-(OH)2D was observed in all 1° HPT cases (P < 0.05), particularly those with low baseline levels.
• Minimal or no significant increase in plasma 1,25-(OH)2D was noted in HP and most PHP cases, except for one normocalcemic PHP patient.

Conclusions:

• Parathyroid function, indicated by 1,25-(OH)2D response to 25OHD3, is significantly altered in primary hyperparathyroidism.
• The response differs markedly between 1° HPT, HP, and PHP, highlighting distinct pathophysiological mechanisms.
• This study provides insights into vitamin D metabolism and parathyroid hormone regulation in different endocrine disorders.